336 related articles for article (PubMed ID: 15199139)
1. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
Danovi D; Meulmeester E; Pasini D; Migliorini D; Capra M; Frenk R; de Graaf P; Francoz S; Gasparini P; Gobbi A; Helin K; Pelicci PG; Jochemsen AG; Marine JC
Mol Cell Biol; 2004 Jul; 24(13):5835-43. PubMed ID: 15199139
[TBL] [Abstract][Full Text] [Related]
2. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
5. Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S; Buckley D; Pang JM; Panimaya J; Paul PJ; Gamell C; Takano EA; Lee YY; Hiddingh S; Rogers TM; Teunisse AF; Herold MJ; Marine JC; Fox SB; Jochemsen A; Haupt Y
Cell Death Dis; 2015 Jul; 6(7):e1821. PubMed ID: 26181202
[TBL] [Abstract][Full Text] [Related]
6. MDMX: from bench to bedside.
Marine JC; Dyer MA; Jochemsen AG
J Cell Sci; 2007 Feb; 120(Pt 3):371-8. PubMed ID: 17251377
[TBL] [Abstract][Full Text] [Related]
7. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.
Wang H; Yan C
Neoplasia; 2011 Jul; 13(7):611-9. PubMed ID: 21750655
[TBL] [Abstract][Full Text] [Related]
8. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
9. Effects of MdmX on Mdm2-mediated downregulation of pRB.
Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
[TBL] [Abstract][Full Text] [Related]
10. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
11. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis.
Mancini F; Gentiletti F; D'Angelo M; Giglio S; Nanni S; D'Angelo C; Farsetti A; Citro G; Sacchi A; Pontecorvi A; Moretti F
J Biol Chem; 2004 Feb; 279(9):8169-80. PubMed ID: 14660608
[TBL] [Abstract][Full Text] [Related]
12. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
13. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
14. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
16. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
17. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
18. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
19. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
